WFG Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

WFG Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$0	Hold	1	–	–	﹤0.01%	1678
2017 Q1	$0	Hold	1	–	–	﹤0.01%	1675
2016 Q4	$0	Sell	1 -20	-95%	-$1.63K	﹤0.01%	1743
2016 Q3	$2K	Hold	21	–	–	﹤0.01%	1414
2016 Q2	$2K	Hold	21	–	–	﹤0.01%	1394
2016 Q1	$2K	Buy	21 +1	+5%	+$90	﹤0.01%	1358
2015 Q4	$3K	Hold	20	–	–	﹤0.01%	1319
2015 Q3	$2K	Hold	20	–	–	﹤0.01%	1438
2015 Q2	$2K	Hold	20	–	–	﹤0.01%	1504
2015 Q1	$2K	Hold	20	–	–	﹤0.01%	1573
2014 Q4	$2K	Hold	20	–	–	﹤0.01%	1882
2014 Q3	$2K	Hold	20	–	–	﹤0.01%	1903
2014 Q2	$2K	Hold	20	–	–	﹤0.01%	1845
2014 Q1	$1K	Hold	20	–	–	﹤0.01%	1920
2013 Q4	$1K	Hold	20	–	–	﹤0.01%	2133
2013 Q3	$2K	Hold	20	–	–	﹤0.01%	1960
2013 Q2	$2K	Buy	+20	New	+$1.47K	﹤0.01%	1872

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

WFG Advisors's VRTX Position: Q2 2017 in Review

WFG Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2017 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

WFG Advisors first reported a position in VRTX in Q2 2013 and has held it in 17 quarters since. The position peaked at $3K in Q4 2015. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

WFG Advisors held 1 share of Vertex Pharmaceuticals worth $0 as of Q2 2017.
WFG Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2017.
Vertex Pharmaceuticals made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1678 holding.
WFG Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
WFG Advisors's Vertex Pharmaceuticals position peaked at $3K in Q4 2015.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.